Coagulation and Hemostasis: Comprehensive Lecture Notes (Coagulation Disorders)

Hemostasis: Overview

Hemostasis is a survival mechanism that rapidly stops bleeding after vessel injury and involves coordinated vascular, cellular (platelet), and enzymatic (coagulation) processes.
Three major steps (vascular/platelet phase to coagulation):
- Vasoconstriction reduces blood flow to the injured site.
- Platelet activation and aggregation form a temporary plug.
- Coagulation cascade forms fibrin threads that stabilize the platelet plug.
Coagulation occurs locally at the injury site; all mechanisms discussed are locally focused.
Key terms to remember:
- Hemostasis vs coagulation: hemostasis = stopping blood loss; coagulation = conversion of soluble proteins to a fibrin mesh that strengthens the clot.
- Platelet surface and coagulation factor interactions occur on the platelet surface during activation.

Platelet Activation: Mechanisms and Receptors

Initiation at injury site:
- Endothelial injury exposes subendothelial matrix, exposing collagen and basal membrane (collagen-rich) that triggers platelet activation.
- Endothelium also releases Von Willebrand Factor (VWF) into circulation and onto injury site.
Endothelial mediators involved in vasoconstriction and platelet recruitment:
- Endothelin: mediates vasoconstriction via vascular smooth muscle cells.
- Prostacyclin (PGI2) and NO: produced by endothelium; oppose platelet activation and promote vasodilation (balance with TXA2).
- VWF is released by endothelial cells and facilitates platelet adhesion by binding exposed collagen and platelets.
Platelet adhesion receptors and ligands:
- Collagen receptor: Gp6 (often referred to as GPVI in modern wording) on platelets recognizes exposed collagen.
- VWF receptor: Gp1b on platelets binds VWF bound to collagen, promoting adhesion.
- After adhesion, platelet activation proceeds via several receptors and signaling pathways.
Platelet activation and shape change:
- Platelets change shape to expose more surface area and agglutinate nearby platelets.
- Activation leads to release of granule contents and synthesis of thromboxane A2 (TXA2).
Primary mediators released by activated platelets (autocrine and paracrine signaling):
- ADP, serotonin (5-HT), and TXA2 are released from platelet granules; TXA2 is synthesized after activation via cyclooxygenase-1 (COX-1).
- Autocrine signaling: ADP acts on the same activated platelet to amplify activation via ADP receptors.
- Paracrine signaling: released mediators activate neighboring platelets to propagate the plug.
Receptors and signaling on platelets:
- ADP receptors: P2Y1 and P2Y12
- Thrombin receptors: PAR1 and PAR4 (protease-activated receptors)
- Gp2b3a receptor (integrin αIIbβ3): binds fibrinogen to cross-link platelets; activation occurs via intracellular pathways including ADP, TXA2, and thrombin signaling.
- Fibrinogen binding to GP2B3A promotes platelet-platelet aggregation (primary aggregation) and bridges platelets into a growing plug.
Central outcomes of platelet activation:
- Shape change and exposure of binding sites for further aggregation.
- Synthesis of TXA2 via COX-1 leading to further platelet activation and vasoconstriction locally.
- Activation of the GP2B3A receptor enabling fibrinogen binding and stabilization of the platelet plug.
Important clinical pharmacology connections:
- GRELs (GP receptor-targeting drugs) inhibit ADP receptors (P2Y1/P2Y12): examples include clopidogrel, prasugrel, ticagrelor.
- Aspirin inhibits COX-1, reducing TXA2 synthesis and thereby reducing platelet activation; covalent binding affords durable inhibition.
- Other COX inhibitors (NSAIDs) are not covalent COX-1 inhibitors like aspirin and have different clinical implications for platelet activation.
Thrombin receptor and platelet activation:
- Thrombin has its own receptors (PAR1, PAR4) on platelets; thrombin promotes platelet activation in addition to its role in coagulation.

The Coagulation Cascade: Extrinsic and Intrinsic Pathways

Overall concept: Activation of coagulation factors on the platelet surface leads to a convergent cascade that forms thrombin, which then converts fibrinogen to fibrin.
Extrinsic pathway (initiates coagulation after injury):
- Tissue factor (TF) exposed at injury site forms a complex with Factor VIIa.
- This complex activates Factor X to Xa: ext{TF} ext{+ VIIa}
  ightarrow ext{Xa}
- Xa then participates in the common pathway to generate thrombin.
Intrinsic pathway (amplifies coagulation on damaged surfaces):
- Begins with Factor XII activation (XIIa) and sequential activation of Factor XI (XIa) and Factor IX (IXa) with Factor VIIIa as a cofactor, all on the platelet surface and in the presence of calcium.
- IXa, with VIIIa and calcium, activates Factor X to Xa: ext{IXa}+ ext{VIIIa}+ ext{Ca}^{2+}
  ightarrow ext{Xa}
Common pathway (convergence of extrinsic and intrinsic):
- Xa converts Prothrombin (Factor II) to Thrombin (Factor IIa): ext{Prothrombin (II)}
  ightarrow ext{Thrombin (IIa)} ext{ via Xa}
- Thrombin then converts Fibrinogen (Soluble) to Fibrin (Insouble): ext{Fibrinogen}
  ightarrow ext{Fibrin} ext{ (via Thrombin)}
- Thrombin also activates Factor XIII to XIIIa, which cross-links fibrin to stabilize the clot: ext{FXIII}
  ightarrow ext{FXIIIa}
Thrombin and platelet activation feedback:
- Thrombin further activates platelets, creating a thrombin burst (positive feedback) that accelerates thrombin generation.
- Thrombin receptors on platelets (PAR1, PAR4) contribute to further platelet activation.
Key target points relevant to drug therapy:
- Factor Xa inhibitors (Xa inhibitors) are discussed as anticoagulants (e.g., rivaroxaban, apixaban, edoxaban).
- Thrombin (IIa) inhibitors or agents that affect thrombin generation impact fibrin formation and platelet activation balance.
Summary of the three most critical components to remember:
- Factor Xa activates thrombin production: ext{Xa}
  ightarrow ext{Thrombin (IIa)}
- Thrombin converts fibrinogen to fibrin: ext{Fibrinogen}
  ightarrow ext{Fibrin}
- Thrombin also activates Factor XIII to cross-link fibrin and strengthens the clot.

Fibrin Formation and Clot Stabilization

Fibrin polymer formation:
- Fibrinogen is soluble; thrombin cleaves fibrinopeptides, converting it to insoluble fibrin monomers that polymerize into a mesh:
  ext{Fibrinogen}
  ightarrow ext{Fibrin monomers}
  ightarrow ext{Fibrin polymer}
- The polymer grows by addition of more fibrin monomers until a mesh is formed.
Cross-linking and strengthening:
- Factor XIIIa cross-links fibrin polymers, producing a stronger, covalently bonded clot: ext{Fibrin polymer}
  ightarrow ext{Cross-linked Fibrin} ext{ (stabilized)}

Platelet and Coagulation Regulation: Balance and Inhibitors

Endothelial contributions to balance:
- Prostacyclin (PGI2) and NO from endothelium inhibit platelet activation and promote vasodilation.
- Endothelial release of tPA (tissue plasminogen activator) is a key trigger for fibrinolysis when needed.
Anticoagulant pathways and inhibitors:
- Antithrombin inhibits thrombin (IIa) and Factor Xa; heparin enhances the activity of antithrombin (a major clinical anticoagulant effect).
- Protein C and Protein S serve anticoagulant roles, helping regulate coagulation factors.
- alpha-2 antiplasmin inhibits plasmin to regulate fibrinolysis; alpha-2 macroglobulin provides broad protease inhibition.
Fibrinolysis and its regulation:
- Endothelial tPA converts plasminogen (circulating) to plasmin, which cleaves fibrin:
  ext{Plasminogen}
  ightarrow ext{Plasmin}
  ightarrow ext{Fibrin cleavage}
  ightarrow ext{Fibrinolysis}
- Localization of plasmin activity is enhanced by plasminogen binding to fibrin, preventing widespread systemic fibrinolysis.
- Checkpoints limit fibrinolysis: PAI-1 and PAI-2 inhibit tPA; alpha-2-antiplasmin inhibits free plasmin.
Balance of procoagulants vs anticoagulants:
- A healthy hemostatic balance requires both procoagulants and anticoagulants to be present in controlled amounts.
- Prostacyclin opposes thromboxane A2; NO and prostacyclin help prevent unchecked platelet activation.
- In addition to aspirin (COX-1 inhibition) and Xa inhibitors, other anticoagulant mechanisms maintain balance.
Clinical relevance of balance:
- Excess procoagulants can predispose to thrombosis; excess anticoagulants can predispose to bleeding.
- Heparin therapy enhances antithrombin to inhibit thrombin and Factor Xa; topical balance with antithrombin and protein C/S maintains hemostasis while preventing excessive clotting.

Drugs and Therapeutic Targets Mentioned in the Session

Antiplatelet drugs (GP receptor targets):
- P2Y receptor inhibitors (GRELs) block ADP signaling: examples include clopidogrel, prasugrel, ticagrelor (target P2Y12).
- GP IIb/IIIa inhibitors (Gp2b3a) block fibrinogen binding and platelet aggregation.
Anticoagulants and the coagulation cascade targets:
- Xa inhibitors: rivaroxaban, apixaban, edoxaban (target Factor Xa).
- Thrombin (IIa) inhibitors and other anticoagulants not detailed here but related to thrombin activity.
Hormonal and endothelial modulators:
- Aspirin: covalently inhibits COX-1, reducing TXA2 synthesis, thereby reducing platelet activation; different from other NSAIDs which do not covalently inhibit COX-1.
- Vorapaxar: a thrombin receptor (PAR-1) antagonist that directly blocks thrombin signaling on platelets.
Other related factors and receptors:
- Collagen receptor: Gp6 (GPVI) on platelets.
- VWF receptor: Gp1b on platelets.
- Thrombin receptors: PAR1 and PAR4 on platelets.
- Fibrinogen receptor: GP2B3A on platelets (αIIbβ3 integrin).
Important note about endothelium-derived mediators:
- PGI2 (prostacyclin) and NO oppose platelet activation; endothelin promotes vasoconstriction; VWF helps platelets adhere at injury sites.

Quick Review: Key Q&A Recap from the Session

Primary ligand for initial platelet adhesion at vascular injury:
- Two major players: collagen and von Willebrand factor (VWF).
- The instructor emphasized that VWF is the primary ligand for initial adhesion to the subendothelial surface via platelet Gp1b, with collagen engaging platelet GPVI (Gp6) downstream.
Fibrogen vs fibrin question:
- Fibrogen is soluble; fibrin is insoluble.
- Thrombin cleaves fibrinogen to form insoluble fibrin that polymerizes to form the clot mesh.
Platelet activation mediators that amplify activation:
- ADP, serotonin (5-HT), and thromboxane A2 (TXA2).
- These mediators promote autocrine and paracrine activation, increasing platelet aggregation and reinforcing the plug.
Positive feedback in platelet activation:
- The release of TXA2 and ADP provides positive feedback by activating more platelets, amplifying the response rapidly.
Receptor nomenclature to know for exam context:
- ADP receptors: P2Y1 and P2Y12
- Thrombin receptors: PAR1 and PAR4
- GP2B3A receptor for fibrinogen-mediated platelet-platelet aggregation
Endothelial and regulatory mediators to remember:
- Endothelin: vasoconstriction
- PGI2 (prostacyclin) and NO: oppose platelet activation
- VWF: mediates platelet adhesion via Gp1b
- tPA (tissue plasminogen activator): endothelial signaling to promote fibrinolysis when needed
Mechanistic overview to connect coagulation and platelet activation:
- Platelet activation provides a surface for coagulation factors to assemble and propagate the coagulation cascade, culminating in thrombin generation and fibrin formation.
Practical drug mechanism links to the cascade:
- Aspirin reduces TXA2 synthesis (COX-1 inhibition).
- P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) block ADP-mediated platelet activation.
- Xa inhibitors block the conversion of prothrombin to thrombin, reducing fibrin formation.
- Vorapaxar blocks thrombin signaling via PAR1 on platelets.
Final note on regulation and safety:
- The hemostatic system balances procoagulant and anticoagulant forces; tipping this balance can lead to bleeding or thrombosis.
- Understanding the local nature of these processes helps explain how targeted therapies can reduce thrombosis with controlled bleeding risk.